Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes
“Bigfoot recognizes the urgent need to provide millions of Americans with affordable access to diabetes care. It is a critical part of our mission,” said
The Bigfoot Unity System, the first and only FDA-cleared dose decision support system based on CGM data for people using multiple daily injections, features smart pen caps compatible with a broad range of disposable insulin pens for both long-acting and rapid-acting insulin. Effective immediately, the system will also be compatible with the following:
- Eli Lilly’s (LLY: NYSE) Insulin Lispro, an unbranded biologic that is the same molecule as Humalog®
- Novo Nordisk’s (NVO:NYSE) Insulin Aspart, an unbranded biologic that is the same molecule as Novolog®
-
ReliON™ NovoLog® insulin, a private brand analog insulin manufactured by
Novo Nordisk and available exclusively at Walmart and Sam’s Club pharmacies; ReliOn is the same molecule as Novolog
The above insulins are available at a list price at least
The Bigfoot Unity system is also now compatible with Eli Lilly’s Lyumjev® (insulin lispro-aabc injection), a new rapid-acting insulin from
The decision to offer lower-priced insulin products as a compatible option with the Bigfoot Unity system is just one step the company is taking to expand access for people with insulin-requiring diabetes. The company is also taking action to make its insulin management technology more broadly available to people in rural communities and is working to improve access for Medicare and Medicaid populations.
About
1 Insulin is now a biologic-what does that mean?,
2 Data on file with
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005060/en/
T +1 260 336 6202
jstebing@healthandcommerce.com
Source: